Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency
Di Chen,Xiaofei Zhu,Wanru Tao,Yan Kong,Yong Huag,Yajun Zhang,Ri Liu,Lingong Jiang,Ying Tang,Haiyan Yu,Qiang Hao,Xiangqun Yang,Hao Zou,Jianming Chen,Ying Lu,Huojun Zhang,Wei Li
DOI: https://doi.org/10.1016/j.jconrel.2020.06.001
IF: 11.467
2020-08-01
Journal of Controlled Release
Abstract:<p>The passive targeting <em>via</em> nanomedicine to pancreatic tumor microenvironment (TME) is identified as an optimized therapeutic strategy for pancreatic ductal adenocarcinoma (PDAC) because lacking specific biomarkers and the intractable anatomical position. Herein, an <em>in vitro</em> 3D PDAC model was set up to evaluate the regulation of extracellular matrix (ECM) by an intelligent system (). This system consisting of a reduction-sensitive core, the payloads of gemcitabine, and the coronal of hyaluronidase arrayed on the cationic surface was fabricated to improve intratumoral penetration and antitumor efficacy. The physicochemical properties, reduction sensitivity, cellular biocompatibility and cytotoxicity, intracellular distribution and therapeutic effects were all evaluated. Particularly, the system showed excellent ECM eradication and <em>in vitro/vivo</em> solid tumor penetration ability as evaluated by home-built equipment and <em>in vitro</em> 3D PDAC model, which confirmed that could be disintegrated in the tumoral reductive cytoplasm after internalization and release gemcitabine to exhibit promoted cytotoxicity. In the <em>in vivo</em> therapy, displayed the highest tumor growth inhibition in PANC-1 tumor-bearing mice with the remarkably increased tumor penetration ability by TME regulation. The results obtained in this study indicate that specifically regulating TME by a well-designed intelligent is promising way for the pancreatic cancer therapy.</p>
pharmacology & pharmacy,chemistry, multidisciplinary